公开(公告)号：US20230181634A1

公开(公告)日：2023-06-15

申请号：US16617487

申请日：2018-05-31

Applicant: Pfizer Inc.

Inventor： Barbra Johnson SASU ,  Danielle Elizabeth DETTLING ,  Cesar Adolfo SOMMER ,  Yik Andy YEUNG ,  Moustafa Marc HAMZE

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705 ,  C07K14/715 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K16/2863 ,  C07K14/70517 ,  C07K14/7151 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/02 ,  C07K2317/622 ,  A61K38/00

Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).

公开(公告)号：US20250011446A1

公开(公告)日：2025-01-09

申请号：US18639749

申请日：2024-04-18

Applicant: Pfizer Inc.

Inventor： Siler PANOWSKI ,  Tao SAI ,  Barbra Johnson SASU ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

公开(公告)号：US20190233528A1

公开(公告)日：2019-08-01

申请号：US16264371

申请日：2019-01-31

Applicant: Pfizer Inc.

Inventor： Surabhi Srivatsa Srinivasan ,  Niranjana Aditi Nagarajan ,  Siler Panowski ,  Yoon Park ,  Tao Sai ,  Barbra Johnson SASU ,  Thomas John Van Blarcom ,  Mathilde Brunnhilde Dusseaux ,  Roman Ariel Galetto

IPC: C07K16/28 ,  C07K14/725 ,  A61K39/00 ,  A61P35/02 ,  A61P35/04

CPC classification number: C07K16/2875 ,  A61K39/001129 ,  A61K39/001138 ,  A61K2039/5156 ,  A61P35/02 ,  A61P35/04 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33

Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

公开(公告)号：US20190241669A1

公开(公告)日：2019-08-08

申请号：US16384719

申请日：2019-04-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien KUO ,  Bijan Andre BOLDAJIPOUR ,  Javier Fernando CHAPARRO RIGGERS ,  Philippe DUCHATEAU ,  Roman Ariel GALETTO ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Arvind RAJPAL ,  Barbra Johnson SASU ,  Cesar Adolfo SOMMER ,  Julien VALTON ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  C07K14/705 ,  A61K31/7076 ,  A61K35/17 ,  C12N15/63 ,  C07K14/725 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/7076 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2863 ,  C07K16/2896 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N15/63

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US20190144550A1

公开(公告)日：2019-05-16

申请号：US16255348

申请日：2019-01-23

Applicant: Pfizer Inc.

Inventor： Oi Kwan WONG ,  Joyce Ching CHOU ,  Mathilde Brunnhilde DUSSEAUX ,  Julianne SMITH ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/47

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US20190194335A1

公开(公告)日：2019-06-27

申请号：US16163243

申请日：2018-10-17

Applicant: Pfizer Inc.

Inventor： Oi Kwan WONG ,  Joyce Ching CHOU ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.